Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 07 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-sep-07-2022-3

Zydus Lifesciences Limited has informed the Exchange about press release dated 07-Sep-2022 titled Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS)

View Attachment

6ix hasn’t read this filing yet.

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases